Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.

Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators.

N Engl J Med. 2013 Mar 21;368(12):1092-100. doi: 10.1056/NEJMoa1301440.

2.

Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.

Khan AR, Bin Abdulhak AA, Sheikh MA, Khan S, Erwin PJ, Tleyjeh I, Khuder S, Eltahawy EA.

JACC Cardiovasc Interv. 2013 Dec;6(12):1316-23. doi: 10.1016/j.jcin.2013.08.001. Epub 2013 Oct 16. Review.

3.

Percutaneous closure versus medical therapy alone for cryptogenic stroke patients with a patent foramen ovale: meta-analysis of randomized controlled trials.

Pickett CA, Villines TC, Ferguson MA, Hulten EA.

Tex Heart Inst J. 2014 Aug 1;41(4):357-67. doi: 10.14503/THIJ-13-3879. eCollection 2014 Aug. Review.

4.

Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack.

Li J, Liu J, Liu M, Zhang S, Hao Z, Zhang J, Zhang C.

Cochrane Database Syst Rev. 2015 Sep 8;(9):CD009938. doi: 10.1002/14651858.CD009938.pub2. Review.

PMID:
26346232
5.

Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.

Rengifo-Moreno P, Palacios IF, Junpaparp P, Witzke CF, Morris DL, Romero-Corral A.

Eur Heart J. 2013 Nov;34(43):3342-52. doi: 10.1093/eurheartj/eht285. Epub 2013 Jul 11. Review.

PMID:
23847132
6.

A meta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events.

Pineda AM, Nascimento FO, Yang SC, Kirtane AJ, Sommer RJ, Beohar N.

Catheter Cardiovasc Interv. 2013 Nov 15;82(6):968-75. doi: 10.1002/ccd.25122. Epub 2013 Aug 5. Review.

PMID:
23832613
7.

Safety and efficacy of device closure for patent foramen ovale for secondary prevention of neurological events: Comprehensive systematic review and meta-analysis of randomized controlled trials.

Hakeem A, Marmagkiolis K, Hacioglu Y, Uretsky BF, Gundogdu B, Leesar M, Bailey SR, Cilingiroglu M.

Cardiovasc Revasc Med. 2013 Nov-Dec;14(6):349-55. doi: 10.1016/j.carrev.2013.08.010. Epub 2013 Sep 27. Review.

PMID:
24080379
8.

Is transcatheter closure better than medical therapy for cryptogenic stroke with patent foramen ovale? A meta-analysis of randomised trials.

Nagaraja V, Raval J, Eslick GD, Burgess D, Denniss AR.

Heart Lung Circ. 2013 Nov;22(11):903-9. doi: 10.1016/j.hlc.2013.07.022. Epub 2013 Sep 10. Review.

PMID:
24035325
9.

PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta-analysis.

Ntaios G, Papavasileiou V, Makaritsis K, Michel P.

Int J Cardiol. 2013 Oct 30;169(2):101-5. doi: 10.1016/j.ijcard.2013.08.058. Epub 2013 Aug 28. Review.

PMID:
24041984
10.

Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis.

Wolfrum M, Froehlich GM, Knapp G, Casaubon LK, DiNicolantonio JJ, Lansky AJ, Meier P.

Heart. 2014 Mar;100(5):389-95. doi: 10.1136/heartjnl-2013-304394. Epub 2013 Jun 21. Review.

PMID:
23793373
11.

Meta-analysis of net long-term benefit of different therapeutic strategies in patients with cryptogenic stroke and patent foramen ovale.

Patti G, Pelliccia F, Gaudio C, Greco C.

Am J Cardiol. 2015 Mar 15;115(6):837-43. doi: 10.1016/j.amjcard.2014.12.051. Epub 2015 Jan 6. Review.

PMID:
25620037
12.

Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence.

Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM.

Stroke. 2012 Feb;43(2):422-31. doi: 10.1161/STROKEAHA.111.631648. Epub 2011 Dec 15. Review.

13.

Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis.

Stortecky S, da Costa BR, Mattle HP, Carroll J, Hornung M, Sievert H, Trelle S, Windecker S, Meier B, Jüni P.

Eur Heart J. 2015 Jan 7;36(2):120-8. doi: 10.1093/eurheartj/ehu292. Epub 2014 Aug 11. Review.

PMID:
25112661
14.

Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Messé SR, Silverman IE, Kizer JR, Homma S, Zahn C, Gronseth G, Kasner SE; Quality Standards Subcommittee of the American Academy of Neurology.

Neurology. 2004 Apr 13;62(7):1042-50. Review.

PMID:
15078999
15.

Patent foramen ovale--assessment and treatment.

Irwin B, Ray S.

Cardiovasc Ther. 2012 Jun;30(3):e128-35. doi: 10.1111/j.1755-5922.2010.00250.x. Epub 2011 Feb 15. Review.

PMID:
21883994
16.

Device Closure of Patent Foramen Ovale After Stroke: Pooled Analysis of Completed Randomized Trials.

Kent DM, Dahabreh IJ, Ruthazer R, Furlan AJ, Reisman M, Carroll JD, Saver JL, Smalling RW, Jüni P, Mattle HP, Meier B, Thaler DE.

J Am Coll Cardiol. 2016 Mar 1;67(8):907-17. doi: 10.1016/j.jacc.2015.12.023. Review.

17.
18.

A systematic review of closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and cryptogenic stroke or transient ischemic attack.

Chen L, Luo S, Yan L, Zhao W.

J Neurol Sci. 2014 Feb 15;337(1-2):3-7. doi: 10.1016/j.jns.2013.11.027. Epub 2013 Nov 26. Review.

PMID:
24300230
19.

Closure of patent foramen ovale in cryptogenic stroke: a never ending story.

Calvet D, Mas JL.

Curr Opin Neurol. 2014 Feb;27(1):13-9. doi: 10.1097/WCO.0000000000000052. Review. Erratum in: Curr Opin Neurol. 2014 Apr;27(2):242.

PMID:
24300793
20.

Patent foramen ovale.

Dattilo PB, Kim MS, Carroll JD.

Cardiol Clin. 2013 Aug;31(3):401-15. doi: 10.1016/j.ccl.2013.05.002. Review.

PMID:
23931102

Supplemental Content

Support Center